Table 1: Baseline characteristics of the cohort of.
Patients baseline characteristics in the whole cohort. Comparison of clinical and laboratory variables between patients in the group with better and worse outcomes, defined as ability to be liberated from mechanical ventilation at day 28 after enrollment. Data are presented as median with interquartile range (IQR); unless otherwise indicated. APACHE II: Acute Physiology and Chronic Health Evaluation II; SAPS II: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment. ECMO: Extracorporeal membrane oxygenation; CRP: C-reactive protein. Significant p values are indicated in bold font.
| Variables | Entire cohort | >0 Ventilatory-free days Better outcome |
0 Ventilatory-free days Worse outcome |
p Value |
|---|---|---|---|---|
| Sex- N (%) | n=41 | n=22 | n=19 | |
| Male | 28 (68.3%) | 15 (68.2%) | 13 (68.4%) | 0.98 |
| Female | 13 (31.7%) | 7 (31.8%) | 6 (31.6%) | 0.98 |
| Age (IQR) | ||||
| 59.9 (50-71.5) | 58.7 (53-67) | 61.2 (46-73) | 0.58 | |
| Ethnicity- N (%) | ||||
| White | 11 (26.8%) | 7 (31.8%) | 4 (21.1%) | 0.44 |
| African American | 5 (12.2%) | 1 (4.5%) | 4 (21.1%) | 0.11 |
| Asian | 2 (5.9%) | 1 (4.5%) | 1 (5.3%) | 0.91 |
| Hispanic | 13 (31.7%) | 5 (22.7%) | 8 (42.1%) | 0.18 |
| Other | 10 (24.4%) | 8 (36.4%) | 2 (10.5%) | 0.06 |
| Comorbidities- N(%) | ||||
| Congestive heart failure | 1 (2.4%) | 1 (4.5%) | 0 (0%) | 0.35 |
| Pulmonary disease | 6 (14.6%) | 5 (22.7%) | 1 (5.3%) | 0.11 |
| Diabetes Mellitus | 16 (39.1%) | 9 (40.9%) | 7 (36.8%) | 0.79 |
| renal Disease | 4 (9.8%) | 1 (4.5%) | 3 (15.8%) | 0.23 |
| Cancer | 2 (4.9%) | 1 (4.5%) | 1 (5.3%) | 0.91 |
| HIV/AIDS | 1 (2.4%) | 1 (4.5%) | 0 (0%) | 0.35 |
| Charlson score index | 3.05 (1-4) | 3.09 (2-3.25) | 3.00 (1-5) | 0.90 |
| Severity scores (IQR) | ||||
| APACHEII | 24.17 (18.5-28.5) | 21.45 (17.75-25.5) | 27.32 (23-33) | <0.01 |
| SAPS II | 59.85 (50.5-68.5) | 56.23 (49.5-59) | 64.05 (58-74) | 0.03 |
| SOFA | 9.54 (7-12) | 8.5 (6.75-10.25) | 10.74 (7-13) | 0.04 |
| Biomarkers (IQR) | ||||
| Ferritin (NG/mL) | 895.33 (376.5-1259) | 724.91 (349.25-901.25) | 1103.61 (685.75-1329) | 0.07 |
| CRP (MG/L) | 179.31 (73.1-256.5) | 170.81 (60.78-255.8) | 190.32 (103.95-258.55) | 0.59 |
| D-dimer (MG/L FEU) | 21.93 (2.12-25.65) | 13.71 (1.66-19.03) | 31.45 (4.11-56.27) | 0.05 |
| Procalcitonin (NG/mL) | 6.35 (0.473-4.34) | 6.43 (0.19-2.37) | 6.27 (0.825-7.205) | 0.97 |
| Lactate (mmol/ L) | 1.25 (0.905-1.51) | 1.25 (0.87-1.56) | 1.26 (0.92-1.39) | 0.94 |
| Fibrinogen (MG/DL) | 556.53 (411.5-685.75) | 555.9 (387-708) | 557.2 (429.5-685.75) | 0.98 |
| Respiratory variables (IQR) | ||||
| P/F Ratio (ml/cmH2O) | 159.15 (98-202.5) | 187.5 (125.75-224) | 126.4 (81-156) | <0.01 |
| Static Compliance (Torr) | 41.05 (28.38-45.1) | 42.19 (29.88-45.05) | 39.72 (28-45.27) | 0.70 |
| Treatment- N (%) | ||||
| ECMO | 2 (4.9%) | 1 (4.5%) | 1 (5.3%) | 0.91 |
| Antibiotics | 41 (100%) | 22 (100%) | 19 (100%) | NA |
| Hydroxychloroquine | 38 (92.7%) | 21(95.5%) | 17(89.5%) | 0.47 |
| Antiviral | 1 (2.4%) | 1 (4.5%) | 0 (0%) | 0.35 |
| IL6- Antagoinist | 2 (4.9%) | 0 (0%) | 2 (10.5%) | 0.12 |
| Convalescent Plasma | 16 (39.1%) | 7 (31.8%) | 9(47.4%) | 0.31 |
| Steroids | 28 (68.3%) | 17 (77.3%) | 11 (57.9%) | 0.18 |
| Outcome Mean (IQR) | ||||
| 28-day vent free day | 8.71 (0-19) | 16.23 (10.5-22.25) | NA | <0.0001 |
| 30-day hospital free day | 4.15 (0-8.5) | 7.32 (0-12.5) | NA | <0.001 |